Carina Rodriguez Archives - USF Health News https://hscweb3.hsc.usf.edu/blog/tag/carina-rodriguez/ USF Health News Tue, 26 Oct 2021 15:57:54 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.3 USF Health a site for clinical trial testing of the Moderna COVID vaccine for children ages 6 months to 5 years https://hscweb3.hsc.usf.edu/blog/2021/10/26/usf-health-a-site-for-clinical-trial-testing-of-the-moderna-covid-vaccine-for-children-ages-6-months-to-5-years/ Tue, 26 Oct 2021 15:44:07 +0000 https://hscweb3.hsc.usf.edu/?p=35260     Children under 12 years old are currently not eligible for the Moderna COVID-19 vaccine. The USF Health Morsani College of Medicine has been selected as one […]

]]>

 

 

Children under 12 years old are currently not eligible for the Moderna COVID-19 vaccine. The USF Health Morsani College of Medicine has been selected as one of several sites conducting trials on Moderna’s coronavirus vaccine for this age group.

The first part of the trial, which focused on children 6-12 years old, is complete. USF Health researchers want to enroll 100 children ages 6 months to 5 years for a second trial by early December.

“A vaccine for children is necessary because they can transmit COVID-19, get sick enough to be hospitalized, experience long COVID—and sadly some children have died from COVID,” said Carina Rodriguez, MD, principal investigator for the Moderna trial at USF.

Carina Rodriguez, MD, principal investigator for the Moderna trial at USF Health.

Dr. Rodriguez, who is also a professor and chief of the Division of Pediatric Infectious Diseases in USF Health’s Department of Pediatrics, said, “the goal is to look for an efficacious and safe COVID vaccine for children.” She continued, “It’s needed to accomplish the end of this pandemic.”

For more information about the trials or enrollment, please send an email to usfchildrenscovidvaccine@gmail.com or call/text at 813-853-1149.



]]>
USF Health a site for clinical trial testing Moderna COVID vaccine for children ages 6 months to under 12 years https://hscweb3.hsc.usf.edu/blog/2021/08/11/usf-health-a-site-for-clinical-trial-testing-moderna-covid-vaccine-for-children-age-6-months-to-11-years/ Wed, 11 Aug 2021 20:07:49 +0000 https://hscweb3.hsc.usf.edu/?p=34588 TAMPA, Fla (August 11, 2021) – The USF Health Morsani College of Medicine has been selected as a site for a clinical trial testing the Moderna mRNA-1273 COVID-19 […]

]]>

TAMPA, Fla (August 11, 2021) – The USF Health Morsani College of Medicine has been selected as a site for a clinical trial testing the Moderna mRNA-1273 COVID-19 vaccine for children ages 6 months to less than 12 years old.

Moderna intends to enroll up to 12,000 pediatric participants in the United States and Canada in this Phase 2/3 research study, called KidCOVE Study. The USF Health research physicians are seeking Tampa Bay area volunteers to participate in the KidCOVE study to evaluate safety and immune responses.  Enrollment begins for USF Health in coming days.

Image courtesy of Moderna.

“USF Health is pleased to join this national clinical trial to determine the safety and effectiveness of Moderna vaccines in children and younger populations,” said Charles Lockwood, MD, senior vice president of USF Health and dean of the USF Health Morsani College of Medicine. “Widespread vaccination is the best defense against COVID-19, and this rigorous scientific study may go a long way toward increasing vaccine access in this younger demographic.”

Leading the USF Health effort as principal investigator is Carina Rodriguez, MD, professor and chief of the Division of Pediatric Infectious Diseases in the Department of Pediatrics in the USF Health Morsani College of Medicine.

“This research study can help provide critical information about the safety, reactogenicity and immune responses observed with the vaccine in children and ultimately allow the vaccine to be approved for children,” Dr. Rodriguez said. “A vaccine that prevents COVID-19 disease in children would be a crucial public health tool to help curb the pandemic. We are eager to contribute to the innovative science that is working to bring a safe and effective solution for our younger patients, who are also vulnerable to this health threat.”

SOFIA. BULGARIA. FEBRUARY 24,2021. A Moderna Covid-19 Vaccine vial with sterile syringes

Participants will be seen by the study team based in USF Health’s Department of Pediatrics. Three out of four children participating in part 2 of the KidCOVE clinical trial will receive two intramuscular injections of the vaccine spaced at four weeks apart. The vaccine is made of messenger ribonucleic acid (mRNA), an instructional code that tells cells how to make protein, which help the body’s immune system make antibodies to fight the virus. The remaining quarter of participants will receive injections of a placebo made of saline (sterile salt water) solution.

All participants will be randomly selected to receive the vaccine or placebo. Participants will be followed for 12 months post-vaccination to monitor their health and safety.

Eligibility criteria

Study volunteers must be:

  • No younger than 6 months and less than 12 years old
  • In good health or with stable chronic conditions

Study volunteers must not:

  • Have received an investigational or approved vaccine for COVID-19
  • Be currently taking any investigational or approved treatments for COVID-19
  • Have tested positive for COVID-19 or been in contact with anyone diagnosed with COVID-19 within 2 weeks prior to vaccine administration
  • Have participated in any clinical trial in the past month

Enrollment for the USF Health Moderna KidCOVE Study begins in coming days, via email (usfchildrenscovidvaccine@gmail.com) or phone/text (813-853-1149).



]]>
USF Health and Tampa General Hospital selected to participate in the Novavax COVID-19 vaccine Phase 3 clinical trial https://hscweb3.hsc.usf.edu/blog/2020/12/02/usf-health-and-tampa-general-hospital-selected-to-participate-in-the-novavax-covid-19-caccine-phase-3-clinical-trial/ Wed, 02 Dec 2020 20:20:32 +0000 https://hscweb3.hsc.usf.edu/?p=32950    Tampa, FL (Dec. 2, 2020) – USF Health and Tampa General Hospital have been selected as a site for a clinical trial testing the Novavax NVX-CoV2373 vaccine […]

]]>

  

Tampa, FL (Dec. 2, 2020) – USF Health and Tampa General Hospital have been selected as a site for a clinical trial testing the Novavax NVX-CoV2373 vaccine for COVID-19. They join over 100 research sites expecting to enroll more than 30,000 adult participants as part of the global search for a safe and effective vaccine to prevent COVID-19.

The USF Health/TGH research physicians are seeking more than 250 Tampa Bay area volunteers to participate in the trial; enrollment is targeted to begin in the next few weeks.

Photo courtesy of Novavax.

The Novavax Phase 3 clinical trial is evaluating NVX-CoV2373, an investigational vaccine that has shown promising results for increasing the body’s immune response to the COVID-19 virus. Clinical trials are used to develop new prevention methods and medical treatments. The research community and study volunteers are critical to demonstrate that a vaccine can reduce the number of outbreaks and deaths caused by COVID-19.

“USF Health is committed to advancing evidence-based medicine, and serving as a site for the Novavax Phase 3 clinical trial of NVX-CoV2373 is an opportunity to join the global effort of securing a successful vaccine,” said Charles J. Lockwood, MD, senior vice president of USF Health and dean of the Morsani College of Medicine. “By engaging in this rigorous scientific study, USF Health will contribute to the discovery of a public health solution that can quickly and safely bring an end to this terrible pandemic. This is just the latest way in which USF Health is combating the epidemic.”

Participating in a complex vaccine trial is possible because of the infrastructure TGH and USF Health have in place as a leading academic medical center, said TGH President and CEO John Couris.

“As an academic medical center, we have the experts and the infrastructure in place to help lead research that will ultimately win the fight against COVID-19,” Couris said. “We are continuing to invest in research and innovation that will push medical discovery forward to help save the lives and health of all Floridians.”

Leading the USF Health/TGH effort as principal investigator is Carina Rodriguez, MD, professor and chief of the Division of Infectious Diseases in the Department of Pediatrics in the USF Health Morsani College of Medicine. This study is one of the phase 3 vaccine trials supported by the COVID-19 Prevention Network (CoVPN), a multisite international collaboration effort funded by the National Institute of Allergy and Infectious Diseases (NIAID) that brought infectious disease experts to address the challenges imposed by the COVID-19 pandemic.

“This study is designed to evaluate the efficacy and safety of the Novavax NVX-CoV2373 vaccine and its ability to prevent COVID-19 illness in individuals 18 years and older. The trial will be inclusive of individuals at risk due to age, occupation, underlying medical conditions, and people of racial and ethnic groups who have been impacted in greater numbers by the pandemic, including African Americans, Latinx, Asian Americans, and Native Americans. We are eager to contribute to the rigorous and innovative science that is working to bring a safe and effective solution to this health threat,” Dr. Rodriguez said.

Photo courtesy of Novavax.

Two out of three people participating in the clinical trial will receive two intramuscular injections of the vaccine spaced at three weeks apart. The vaccine is designed to prevent COVID-19 by stimulating the immune response against the virus and helping to create neutralizing antibodies to fight COVID-19 infection. The remaining 1/3 of participants will receive injections of a placebo made of saline (sterile salt water) solution.

All participants will be randomly selected to receive the vaccine or placebo. Participants will be followed for 24 months post-vaccination to monitor their health and safety.

Having some people receive the investigational vaccine and others receive placebo is the best way to determine whether the vaccine is effective in preventing disease. To find out more about this clinical trial, please visit ClinicalTrials.gov

Enrollment information for participating in the USF Health/TGH COVID-19 clinical trial will be shared in the coming weeks.

 

ABOUT USF HEALTH
USF Health’s mission is to envision and implement the future of health. It is the partnership of the USF Health Morsani College of Medicine, the College of Nursing, the College of Public Health, the Taneja College of Pharmacy, the School of Physical Therapy and Rehabilitation Sciences, the Biomedical Sciences Graduate and Postdoctoral Programs, and USF Health’s multispecialty physicians group. The University of South Florida is a high-impact global research university dedicated to student success. Over the past 10 years, no other public university in the country has risen faster in U.S. News & World Report’s national university rankings than USF. For more information, visit health.usf.edu

ABOUT TAMPA GENERAL HOSPITAL
Tampa General Hospital, a 1006-bed non-profit academic medical center, is one of the largest hospitals in America and delivers world-class care as the region’s only center for Level l trauma and comprehensive burn care. It is one of the nation’s busiest adult solid organ transplant centers and is the primary teaching hospital for the USF Health Morsani College of Medicine. With five medical helicopters, Tampa General Hospital transports critically injured or ill patients from 23 surrounding counties to receive the advanced care they need. Tampa General houses a nationally accredited comprehensive stroke center and its 32-bed Neuroscience Intensive Care Unit is the largest on the West Coast of FloridaIt also is home to the Jennifer Leigh Muma 82-bed Level IV neonatal intensive care unit, and a nationally accredited rehabilitation center. Tampa General Hospital’s footprint includes 17 Tampa General Medical Group Primary Care offices, TGH Family Care Center Kennedy, TGH Brandon Healthplex, TGH Virtual Health and 19 outpatient Radiology Centers. Tampa Bay residents also receive world-class care from the TGH Urgent Care powered by Fast Track network of clinics, and they can even receive home visits in select areas through TGH Urgent Care at Home, powered by Fast Track.  As one of the largest hospitals in Florida, Tampa General Hospital is first in the state to partner with GE Healthcare and open a clinical command center that uses artificial intelligence and predictive analytics to improve and better coordinate patient care at a lower cost.  For more information, go to www.tgh.org.

 

 



]]>